Regeneron Pharmaceuticals and Parabilis Medicines have entered a strategic collaboration worth over $2.3 billion to develop a new class of antibody-peptide conjugates targeting historically undruggable intracellular proteins. This partnership is significant for tech and biotech professionals because it combines antibody-targeted cell delivery with stabilized helical peptide payloads designed to engage complex protein surfaces that resist traditional small-molecule binding. Success in this venture could establish an entirely new therapeutic category capable of modulating previously inaccessible disease drivers across multiple therapeutic areas.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
